| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 149, 2023-2035, Copyright © 1996 by American Society for Investigative Pathology
REGULAR ARTICLES |
M Gambacorta, L Flenghi, M Fagioli, S Pileri, L Leoncini, B Bigerna, R Pacini, LN Tanci, L Pasqualucci, S Ascani, A Mencarelli, A Liso, PG Pelicci and B Falini
Institute of Pathology, Ospedale Niguarda, Milan, Italy.
The RING-finger promyelocytic leukemia (PML) protein is the product of the PML gene that fuses with the retinoic acid receptor-alpha gene in the t(15; 17) translocation of acute promyelocytic leukemia. Wild-type PML localizes in the nucleus with a typical speckled pattern that is a consequence of the concentration of the protein within discrete subnuclear domains known as nuclear bodies. Delocalization of PML from nuclear bodies has been documented in acute promyelocytic leukemia cells and suggested to contribute to leukemogenesis. In an attempt to get new insights into the function of the wild-type PML protein and to investigate whether it displays an altered expression pattern in neoplasms other than acute promyelocytic leukemia, we stained a large number of normal and neoplastic human tissues with a new murine monoclonal antibody (PG-M3) directed against the amino-terminal region of PML. As the PG-M3 epitope is partially resistant to fixatives, only cells that overexpress PML are detected by the antibody in microwave- heated paraffin sections. Among normal tissues, PML was characteristically up-regulated in activated epithelioid histiocytes and fibroblasts in a variety of pathological conditions, columnar epithelium in small active thyroid follicles, well differentiated foamy cells in the center of sebaceous glands, and hypersecretory endometria (Arias-Stella). Interferons, the PML of which is a primary target gene, and estrogens are likely to represent some of the cytokines and/or hormones that may be involved in the up-regulation of PML under these circumstances. In keeping with this concept, we found that PML is frequently overexpressed in Hodgkin and Reed-Sternberg cells of Hodgkin's disease, a tumor of cytokine-producing cells. Among solid tumors, overexpression of PML was frequently found in carcinomas of larynx and thyroid (papillary), epithelial thymomas, and Kaposi's sarcoma, whereas carcinomas of the lung, thyroid (follicular), breast, and colon were frequently negative or weakly PML+. We did not observe any changes in the levels of PML expression as the lesion progressed from benign dysplasia to carcinoma. Our immunohistological data are consistent with the hypothesized growth suppressor function of PML and strongly suggest that PML expression levels are likely to be modulated by a variety of stimuli, including cytokines and hormones.
This article has been cited by other articles:
 |
|
 |
|
  S. Weidtkamp-Peters, T. Lenser, D. Negorev, N. Gerstner, T. G. Hofmann, G. Schwanitz, C. Hoischen, G. Maul, P. Dittrich, and P. Hemmerich Dynamics of component exchange at PML nuclear bodies J. Cell Sci., August 15, 2008; 121(16): 2731 - 2743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. O. Boe, M. Haave, A. Jul-Larsen, A. Grudic, R. Bjerkvig, and P. E. Lonning Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA J. Cell Sci., August 15, 2006; 119(16): 3284 - 3295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Dmitrovsky Tissue Microarrays for Hypothesis Generation J Natl Cancer Inst, February 18, 2004; 96(4): 248 - 249. [Full Text] [PDF]
|
|
|
|
|
|
C. Gurrieri, P. Capodieci, R. Bernardi, P. P. Scaglioni, K. Nafa, L. J. Rush, D. A. Verbel, C. Cordon-Cardo, and P. P. Pandolfi Loss of the Tumor Suppressor PML in Human Cancers of Multiple Histologic Origins J Natl Cancer Inst, February 18, 2004; 96(4): 269 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-X. Xu, R.-X. Zhao, T. Ding, T. T. Tran, W. Zhang, P. P. Pandolfi, and K.-S. Chang Promyelocytic Leukemia Protein 4 Induces Apoptosis by Inhibition of Survivin Expression J. Biol. Chem., January 16, 2004; 279(3): 1838 - 1844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Falini and D. Y. Mason Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry Blood, January 15, 2002; 99(2): 409 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Melnick and J. D. Licht Deconstructing a Disease: RAR{alpha}, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia Blood, May 15, 1999; 93(10): 3167 - 3215. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Rousselot, S. Labaume, J.-P. Marolleau, J. Larghero, M.-H. Noguera, J.-C. Brouet, and J.-P. Fermand Arsenic Trioxide and Melarsoprol Induce Apoptosis in Plasma Cell Lines and in Plasma Cells from Myeloma Patients Cancer Res., March 1, 1999; 59(5): 1041 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Falini, B. Bigerna, M. Fizzotti, K. Pulford, S. A. Pileri, G. Delsol, A. Carbone, M. Paulli, U. Magrini, F. Menestrina, et al. ALK Expression Defines a Distinct Group of T/Null Lymphomas (""ALK Lymphomas"") with a Wide Morphological Spectrum Am. J. Pathol., September 1, 1998; 153(3): 875 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sternsdorf, K. Jensen, and H. Will Evidence for Covalent Modification of the Nuclear Dot-associated Proteins PML and Sp100 by PIC1/SUMO-1 J. Cell Biol., December 29, 1997; 139(7): 1621 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Falini, L. Flenghi, M. Fagioli, F. L. Coco, I. Cordone, D. Diverio, L. Pasqualucci, A. Biondi, D. Riganelli, A. Orleth, et al. Immunocytochemical Diagnosis of Acute Promyelocytic Leukemia (M3) With the Monoclonal Antibody PG-M3 (Anti-PML) Blood, November 15, 1997; 90(10): 4046 - 4053. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
